U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H28O2
Molecular Weight 300.4359
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 4
Charge 0

SHOW SMILES / InChI
Structure of TRETINOIN

SMILES

C/C(=C(/[H])\C(\[H])=C(/[H])\C(=C(/[H])\C(=O)O)\C)/C(/[H])=C(\[H])/C1=C(C)CCCC1(C)C

InChI

InChIKey=SHGAZHPCJJPHSC-YCNIQYBTSA-N
InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14+

HIDE SMILES / InChI

Molecular Formula C20H28O2
Molecular Weight 300.4359
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 4
Optical Activity NONE

All-trans retinoic acid (ATRA) also known as tretinoin is an active metabolite of vitamin A that has been demonstrated to inhibit the growth of cancer cells, some types of epithelial cells, and vascular smooth muscles. It is medication used for the treatment of acne. Tretinoin capsules are indicated for the induction of remission in patients with acute promyelocytic leukemia (APL), French-American-British (FAB) classification M3 (including the M3 variant), characterized by the presence of the t(15;17) translocation and/or the presence of the PML/RARα gene who are refractory to, or who have relapsed from, anthracycline chemotherapy, or for whom anthracycline based chemotherapy is contraindicated. Tretinoin is for the induction of remission only. For acne it is applied to the skin as a cream or ointment. For leukemia it is taken by mouth for up to three months. The exact mechanism of action of tretinoin in APL and acne treatment is unknown, but is known, that tretinoin activates three members of the retinoid acid (RAR) nuclear receptors (RARα, RARβ, and RARγ) which act to modify gene expression, subsequent protein synthesis, and epithelial cell growth and differentiation. It has not been established whether the clinical effects of tretinoin are mediated through activation of retinoic acid receptors, other mechanisms, or both.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
RETIN-A

Approved Use

RETIN-A is indicated for topical application in the treatment of acne vulgaris. The safety and efficacy of the long-term use of this product in the treatment of other disorders have not been established.

Launch Date

5.6764801E10
Palliative
TRETINOIN

Approved Use

retinoin Capsules are indicated for the induction of remission in patients with acute promyelocytic leukemia (APL), French-American-British (FAB) classification M3 (including the M3 variant), characterized by the presence of the t(15;17) translocation and/or the presence of the PML/RARα gene who are refractory to, or who have relapsed from, anthracycline chemotherapy, or for whom anthracycline based chemotherapy is contraindicated. Tretinoin is for the induction of remission only. The optimal consolidation or maintenance regimens have not been defined, but all patients should receive an accepted form of remission consolidation and/or maintenance therapy for APL after completion of induction therapy with tretinoin.

Launch Date

1.18247037E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
314 ng/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ISOTRETINOIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4055 ng × h/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ISOTRETINOIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
24 h
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ISOTRETINOIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
0.1%
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ISOTRETINOIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
12.5 mg/kg single, oral
Overdose
Dose: 12.5 mg/kg
Route: oral
Route: single
Dose: 12.5 mg/kg
Sources: Page: p.348
unhealthy, 29
n = 1
Health Status: unhealthy
Condition: Acne
Age Group: 29
Sex: M
Population Size: 1
Sources: Page: p.348
Disc. AE: Cheilitis, Skin xerosis...
AEs leading to
discontinuation/dose reduction:
Cheilitis
Skin xerosis
Desquamation
Headache
Skin xerosis
Sources: Page: p.348
1000 mg single, oral
Overdose
Dose: 1000 mg
Route: oral
Route: single
Dose: 1000 mg
Sources: Page: p.74
unhealthy, 31
n = 1
Health Status: unhealthy
Condition: AIDS
Age Group: 31
Sex: M
Population Size: 1
Sources: Page: p.74
Disc. AE: Diarrhea...
AEs leading to
discontinuation/dose reduction:
Diarrhea
Sources: Page: p.74
100 mg/m2 2 times / day multiple, oral
Highest studied dose
Dose: 100 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg/m2, 2 times / day
Sources: Page: p.897
unhealthy, 4
n = 9
Health Status: unhealthy
Condition: Neuroblastoma
Age Group: 4
Sex: M+F
Population Size: 9
Sources: Page: p.897
DLT: Hypercalcemia, Skin toxicity...
Dose limiting toxicities:
Hypercalcemia (grade 4, 22.2%)
Skin toxicity (grade 3, 33.3%)
Anemia (grade 3, 11.1%)
Thrombocytopenia (grade 3, 11.1%)
Emesis (grade 3, 11.1%)
Hypercalcemia (grade 3, 11.1%)
Sources: Page: p.897
80 mg/m2 2 times / day multiple, oral
MTD
Dose: 80 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 80 mg/m2, 2 times / day
Sources: Page: p.897
unhealthy, 4
n = 23
Health Status: unhealthy
Condition: Neuroblastoma
Age Group: 4
Sex: M+F
Population Size: 23
Sources: Page: p.897
DLT: Hypercalcemia, Skin toxicity...
Dose limiting toxicities:
Hypercalcemia (grade 4, 4.3%)
Skin toxicity (grade 3, 17.4%)
Emesis (grade 3, 4.3%)
AST/ALT ratio abnormal (grade 3, 4.3%)
Sources: Page: p.897
80 mg/m2 2 times / day multiple, oral
MTD
Dose: 80 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 80 mg/m2, 2 times / day
Sources: Page: p.34
unhealthy, 4
n = 16
Health Status: unhealthy
Condition: Neuroblastoma
Age Group: 4
Sex: M+F
Population Size: 16
Sources: Page: p.34
1 mg/kg 2 times / day multiple, oral
Recommended
Dose: 1 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 1 mg/kg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acne
Sources: Page: p.1
Disc. AE: Fetal damage...
AEs leading to
discontinuation/dose reduction:
Fetal damage (grade 4)
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Cheilitis Disc. AE
12.5 mg/kg single, oral
Overdose
Dose: 12.5 mg/kg
Route: oral
Route: single
Dose: 12.5 mg/kg
Sources: Page: p.348
unhealthy, 29
n = 1
Health Status: unhealthy
Condition: Acne
Age Group: 29
Sex: M
Population Size: 1
Sources: Page: p.348
Desquamation Disc. AE
12.5 mg/kg single, oral
Overdose
Dose: 12.5 mg/kg
Route: oral
Route: single
Dose: 12.5 mg/kg
Sources: Page: p.348
unhealthy, 29
n = 1
Health Status: unhealthy
Condition: Acne
Age Group: 29
Sex: M
Population Size: 1
Sources: Page: p.348
Headache Disc. AE
12.5 mg/kg single, oral
Overdose
Dose: 12.5 mg/kg
Route: oral
Route: single
Dose: 12.5 mg/kg
Sources: Page: p.348
unhealthy, 29
n = 1
Health Status: unhealthy
Condition: Acne
Age Group: 29
Sex: M
Population Size: 1
Sources: Page: p.348
Skin xerosis Disc. AE
12.5 mg/kg single, oral
Overdose
Dose: 12.5 mg/kg
Route: oral
Route: single
Dose: 12.5 mg/kg
Sources: Page: p.348
unhealthy, 29
n = 1
Health Status: unhealthy
Condition: Acne
Age Group: 29
Sex: M
Population Size: 1
Sources: Page: p.348
Skin xerosis Disc. AE
12.5 mg/kg single, oral
Overdose
Dose: 12.5 mg/kg
Route: oral
Route: single
Dose: 12.5 mg/kg
Sources: Page: p.348
unhealthy, 29
n = 1
Health Status: unhealthy
Condition: Acne
Age Group: 29
Sex: M
Population Size: 1
Sources: Page: p.348
Diarrhea Disc. AE
1000 mg single, oral
Overdose
Dose: 1000 mg
Route: oral
Route: single
Dose: 1000 mg
Sources: Page: p.74
unhealthy, 31
n = 1
Health Status: unhealthy
Condition: AIDS
Age Group: 31
Sex: M
Population Size: 1
Sources: Page: p.74
Anemia grade 3, 11.1%
DLT
100 mg/m2 2 times / day multiple, oral
Highest studied dose
Dose: 100 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg/m2, 2 times / day
Sources: Page: p.897
unhealthy, 4
n = 9
Health Status: unhealthy
Condition: Neuroblastoma
Age Group: 4
Sex: M+F
Population Size: 9
Sources: Page: p.897
Emesis grade 3, 11.1%
DLT
100 mg/m2 2 times / day multiple, oral
Highest studied dose
Dose: 100 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg/m2, 2 times / day
Sources: Page: p.897
unhealthy, 4
n = 9
Health Status: unhealthy
Condition: Neuroblastoma
Age Group: 4
Sex: M+F
Population Size: 9
Sources: Page: p.897
Hypercalcemia grade 3, 11.1%
DLT
100 mg/m2 2 times / day multiple, oral
Highest studied dose
Dose: 100 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg/m2, 2 times / day
Sources: Page: p.897
unhealthy, 4
n = 9
Health Status: unhealthy
Condition: Neuroblastoma
Age Group: 4
Sex: M+F
Population Size: 9
Sources: Page: p.897
Thrombocytopenia grade 3, 11.1%
DLT
100 mg/m2 2 times / day multiple, oral
Highest studied dose
Dose: 100 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg/m2, 2 times / day
Sources: Page: p.897
unhealthy, 4
n = 9
Health Status: unhealthy
Condition: Neuroblastoma
Age Group: 4
Sex: M+F
Population Size: 9
Sources: Page: p.897
Skin toxicity grade 3, 33.3%
DLT
100 mg/m2 2 times / day multiple, oral
Highest studied dose
Dose: 100 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg/m2, 2 times / day
Sources: Page: p.897
unhealthy, 4
n = 9
Health Status: unhealthy
Condition: Neuroblastoma
Age Group: 4
Sex: M+F
Population Size: 9
Sources: Page: p.897
Hypercalcemia grade 4, 22.2%
DLT
100 mg/m2 2 times / day multiple, oral
Highest studied dose
Dose: 100 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg/m2, 2 times / day
Sources: Page: p.897
unhealthy, 4
n = 9
Health Status: unhealthy
Condition: Neuroblastoma
Age Group: 4
Sex: M+F
Population Size: 9
Sources: Page: p.897
Skin toxicity grade 3, 17.4%
DLT
80 mg/m2 2 times / day multiple, oral
MTD
Dose: 80 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 80 mg/m2, 2 times / day
Sources: Page: p.897
unhealthy, 4
n = 23
Health Status: unhealthy
Condition: Neuroblastoma
Age Group: 4
Sex: M+F
Population Size: 23
Sources: Page: p.897
AST/ALT ratio abnormal grade 3, 4.3%
DLT
80 mg/m2 2 times / day multiple, oral
MTD
Dose: 80 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 80 mg/m2, 2 times / day
Sources: Page: p.897
unhealthy, 4
n = 23
Health Status: unhealthy
Condition: Neuroblastoma
Age Group: 4
Sex: M+F
Population Size: 23
Sources: Page: p.897
Emesis grade 3, 4.3%
DLT
80 mg/m2 2 times / day multiple, oral
MTD
Dose: 80 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 80 mg/m2, 2 times / day
Sources: Page: p.897
unhealthy, 4
n = 23
Health Status: unhealthy
Condition: Neuroblastoma
Age Group: 4
Sex: M+F
Population Size: 23
Sources: Page: p.897
Hypercalcemia grade 4, 4.3%
DLT
80 mg/m2 2 times / day multiple, oral
MTD
Dose: 80 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 80 mg/m2, 2 times / day
Sources: Page: p.897
unhealthy, 4
n = 23
Health Status: unhealthy
Condition: Neuroblastoma
Age Group: 4
Sex: M+F
Population Size: 23
Sources: Page: p.897
Fetal damage grade 4
Disc. AE
1 mg/kg 2 times / day multiple, oral
Recommended
Dose: 1 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 1 mg/kg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acne
Sources: Page: p.1
Overview

Overview

Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
minor
minor
minor
minor
minor
no
no
no
no
no
no
no
yes
yes
yes
yes
yes
PubMed

PubMed

TitleDatePubMed
[Fatal side-effects of all-trans retinoic acid in the treatment of acute promyelocytic leukemia].
1999
Coronaric thrombotic events in acute promyelocytic leukemia during all-trans retinoic acid treatment: a role for adhesion molecules overexpression?
1999 Feb
Tissue factors on acute promyelocytic leukemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents.
1999 Jul
Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia.
1999 Nov
Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia.
2000 Feb
Fatty acid binding proteins from different tissues show distinct patterns of fatty acid interactions.
2000 Jun 20
Thrombosis during all-trans-retinoic acid therapy in a child with acute promyelocytic leukemia and factor VQ 506 mutation.
2000 Mar
[Effects of all-trans retinoic acid and arsenic trioxide on tissue factor expression of acute promyelocytic leukemia cells].
2000 May
Glucuronidation of estrogens and retinoic acid and expression of UDP-glucuronosyltransferase 2B7 in human intestinal mucosa.
2000 Oct
Structural basis for isotype selectivity of the human retinoic acid nuclear receptor.
2000 Sep 8
Carnosic acid and promotion of monocytic differentiation of HL60-G cells initiated by other agents.
2001 Aug 15
Retinoic acid-mediated growth arrest requires ubiquitylation and degradation of the F-box protein Skp2.
2001 Dec 7
Retinoid receptors in human breast carcinoma: possible modulators of in situ estrogen metabolism.
2001 Jan
Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo.
2001 Jan 1
Analysis of cartilage-derived retinoic acid-sensitive protein in cerebrospinal fluid From patients With spinal diseases.
2001 Jan 15
Short heterodimer partner (SHP) orphan nuclear receptor inhibits the transcriptional activity of aryl hydrocarbon receptor (AHR)/AHR nuclear translocator (ARNT).
2001 Jun 1
Interleukin-1beta enhances retinoic acid-mediated expression of bone-type alkaline phosphatase in rat IEC-6 cells.
2001 Mar
Transient dilated cardiomyopathy in a newborn exposed to idarubicin and all-trans-retinoic acid (ATRA) early in the second trimester of pregnancy.
2002 Jul-Aug
All trans retinoic acid enhances CDDP-induced apoptosis: modulation of the CDDP effect on cell cycle progression.
2002 Jun
Patents

Sample Use Guides

acute promyelocytic leukemia (APL): The recommended dose is 45 mg/m2/day administered as two evenly divided doses until complete remission is documented. Therapy should be discontinued 30 days after achievement of complete remission or after 90 days of treatment, whichever occurs first. acne vulgaris: RETIN-A Gel, Cream or Liquid should be applied once a day, before retiring, to the skin where acne lesions appear, using enough to cover the entire affected area lightly. Liquid: the liquid may be applied using a fingertip, gauze pad, or cotton swab. If gauze or cotton is employed, care should be taken not to oversaturate it, to the extent that the liquid would run into areas where treatment is not intended. Gel: Excessive application results in “pilling” of the gel, which minimizes the likelihood of over application by the patient.
Route of Administration: Other
Human bronchial SMCs were used and pretreated with or without tretinoin, also known as all-trans-retinoic acid (ATRA), (2 μM) for 20 min before the addition of PDGF (1 μg/ml), or ATRA alone. The neutral comet assay, which determines the incidence of double-stranded DNA breaks, was used to demonstrate that ATRA treatment induced apoptosis of bovine and human pulmonary artery SMC. In contrast, apoptotic cell death was not produced in response to ATRA in human bronchial airway SMC, as monitored by comet assay. Similarly, TUNEL assay and the measurement of mitochondrial membrane potential failed to demonstrate significant apoptosis by ATRA in airway SMCs. Positive controls, daunorubicin (DNR) and hydrogen peroxide, effectively elicited apoptosis in airway SMC. Because ATRA inhibited both morphologic and actin cytoskeletal changes induced by PDGF, it was characterized the effects of ATRA on PDGF-induced airway SMC migration using a modified Boyden chamber assay, which allows for determination of motility in random directions. PDGF caused a 4-fold increase in migration of airway SMCs after 24 h, and ATRA blocked these events. ATRA by itself had no effect. While the therapeutic level of ATRA in human plasma could reach 1–2 μM, the effects on airway SMC migration were observed with ATRA concentrations as low as 0.2 μM. DMSO, which is used as vehicle for ATRA and other retinoids, has no effect on PDGF-induced airway SMC migration. This does not appear to be due to the effects of ATRA on cell proliferation, as MTT assay showed that ATRA is not effective in inhibiting PDGF-induced cell proliferation; additionally, migration assay with 4 h of PDGF treatment also exhibits the ability of ATRA to inhibit migratory responses, as monitored using a modified Boyden chamber assay. Thus, although ATRA is ineffective in inhibiting proliferation and inducing apoptosis of airway SMCs, ATRA is an efficient inhibitor of airway SMC migration. Furthermore, using actinomycin D, a general inhibitor of gene transcription, showed that ATRA inhibition of SMC migration does not mediate gene transcriptional events.
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:57:59 UTC 2021
Edited
by admin
on Fri Jun 25 20:57:59 UTC 2021
Record UNII
5688UTC01R
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TRETINOIN
EP   HSDB   INN   JAN   MART.   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
TRETINOIN [ORANGE BOOK]
Common Name English
ORISTAR RNA
Brand Name English
TRETINOIN [JAN]
Common Name English
RETINOIC ACID [MI]
Common Name English
RETIN-A
Brand Name English
TRETINOIN COMPONENT OF VELTIN
Brand Name English
TRETINOIN COMPONENT OF SOLAGE
Common Name English
TRETINOIN [USP-RS]
Common Name English
TRI-LUMA COMPONENT TRETINOIN
Common Name English
SOLAGE COMPONENT TRETINOIN
Common Name English
VESANOID
Brand Name English
TRETINOIN [VANDF]
Common Name English
RETINOIC ACID
INCI   MI  
INCI  
Official Name English
RETIN A
Brand Name English
TRETINOIN [USAN]
Common Name English
TRETINOIN [MART.]
Common Name English
TRETINOIN [HSDB]
Common Name English
NSC-122758
Code English
TRETINOIN COMPONENT OF TRI-LUMA
Common Name English
TRETINOIN [USP]
Common Name English
KERLOCAL
Brand Name English
TRETINOIN [USP MONOGRAPH]
Common Name English
TRETINOIN [WHO-DD]
Common Name English
ZIANA COMPONENT TRETINOIN
Common Name English
TRETINOIN COMPONENT OF ZIANA
Common Name English
TRETINOIN [INN]
Common Name English
TRETINOIN [EP MONOGRAPH]
Common Name English
RENOVA
Brand Name English
ATRA
Common Name English
ALTRENO
Brand Name English
EUDYNA
Brand Name English
ABEREL
Brand Name English
ALL-TRANS-RETINOIC ACID
Common Name English
ALL-TRANS RETINOIC ACID
Common Name English
AVITA
Brand Name English
VELTIN COMPONENT TRETINOIN
Brand Name English
RETINOIC ACID [INCI]
Common Name English
Classification Tree Code System Code
NDF-RT N0000007700
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
NDF-RT N0000175607
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
NCI_THESAURUS C68299
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
WHO-VATC QL01XX14
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
FDA ORPHAN DRUG 71692
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
NCI_THESAURUS C804
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
FDA ORPHAN DRUG 5785
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
FDA ORPHAN DRUG 165802
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
LOINC 87673-0
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
WHO-VATC QD10AD51
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
FDA ORPHAN DRUG 50990
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
WHO-ATC D10AD51
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
NDF-RT N0000007700
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
NDF-RT N0000007700
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
WHO-ATC D10AD01
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
WHO-VATC QD10AD01
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
WHO-ATC L01XX14
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
NDF-RT N0000007700
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
NDF-RT N0000007700
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
LIVERTOX 993
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
Code System Code Type Description
ChEMBL
CHEMBL38
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
PRIMARY
DRUG CENTRAL
2722
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
PRIMARY
MERCK INDEX
M9558
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
PRIMARY Merck Index
INN
2875
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
PRIMARY
PUBCHEM
444795
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
PRIMARY
FDA UNII
5688UTC01R
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
PRIMARY
RXCUI
221175
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
ALTERNATIVE
NCI_THESAURUS
C900
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
PRIMARY
WIKIPEDIA
TRETINOIN
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
PRIMARY
RXCUI
10753
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
PRIMARY
DRUG BANK
DB00755
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
PRIMARY
LACTMED
Tretinoin
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
PRIMARY
CAS
302-79-4
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
PRIMARY
IUPHAR
2644
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
PRIMARY
HSDB
2169
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
PRIMARY
EVMPD
SUB11246MIG
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
PRIMARY
EPA CompTox
302-79-4
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
PRIMARY
USP_CATALOG
1674004
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
PRIMARY USP-RS
ECHA (EC/EINECS)
206-129-0
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
PRIMARY
MESH
D014212
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> AGONIST
SALT/SOLVATE -> PARENT
TARGET -> AGONIST
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
METABOLITE -> PARENT
PARENT -> METABOLITE
Mediator Substance AOX1
METABOLITE -> PARENT
METABOLITE -> PARENT
MAJOR
PLASMA
METABOLITE -> PARENT
MAJOR
PLASMA
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY